Targeting pml-rarα with retinoids

Eytan M. Stein; Martin S. Tallman

doi:10.1007/978-1-4939-1393-0_25

Targeting pml-rarα with retinoids

Eytan M. Stein, Martin S. Tallman^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

All-trans retinoic acid (ATRA), an oral retinoic acid derivative, revolutionized the treatment and prognosis of acute promyelocytic leukemia (APL) and anticipated the current age of targeted cancer therapy. The past 25 years have seen an international effort to design multicenter clinical trials that identify the optimal use of ATRA in patients with APL. Indeed, since ATRA is so effective, contemporary clinical trials aim to de-escalate conventional cytotoxic chemotherapy, as has been the case with other highly curable malignancies such as childhood acute lymphoblastic leukemia and Hodgkin’s lymphoma. In this chapter, we review and reflect upon the seminal clinical trials that have led to the current adoption of ATRA as the standard of care for treating APL.

Original language	English (US)
Title of host publication	Targeted Therapy of Acute Myeloid Leukemi
Publisher	Springer New York
Pages	489-507
Number of pages	19
ISBN (Electronic)	9781493913930
ISBN (Print)	9781493913923
DOIs	https://doi.org/10.1007/978-1-4939-1393-0_25
State	Published - Jan 1 2015

Keywords

Acute promyelocytic leukemia
All-trans retinoic acid
Consolidation
Induction
Maintenance

ASJC Scopus subject areas

Medicine(all)
Pharmacology, Toxicology and Pharmaceutics(all)
Biochemistry, Genetics and Molecular Biology(all)
Immunology and Microbiology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-4939-1393-0_25

Cite this

@inbook{d34b0e9a1f8c4e3c920c9004baf6d38a,

title = "Targeting pml-rarα with retinoids",

abstract = "All-trans retinoic acid (ATRA), an oral retinoic acid derivative, revolutionized the treatment and prognosis of acute promyelocytic leukemia (APL) and anticipated the current age of targeted cancer therapy. The past 25 years have seen an international effort to design multicenter clinical trials that identify the optimal use of ATRA in patients with APL. Indeed, since ATRA is so effective, contemporary clinical trials aim to de-escalate conventional cytotoxic chemotherapy, as has been the case with other highly curable malignancies such as childhood acute lymphoblastic leukemia and Hodgkin{\textquoteright}s lymphoma. In this chapter, we review and reflect upon the seminal clinical trials that have led to the current adoption of ATRA as the standard of care for treating APL.",

keywords = "Acute promyelocytic leukemia, All-trans retinoic acid, Consolidation, Induction, Maintenance",

author = "Stein, {Eytan M.} and Tallman, {Martin S.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-1-4939-1393-0_25",

language = "English (US)",

isbn = "9781493913923",

pages = "489--507",

booktitle = "Targeted Therapy of Acute Myeloid Leukemi",

publisher = "Springer New York",

}

TY - CHAP

T1 - Targeting pml-rarα with retinoids

AU - Stein, Eytan M.

AU - Tallman, Martin S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - All-trans retinoic acid (ATRA), an oral retinoic acid derivative, revolutionized the treatment and prognosis of acute promyelocytic leukemia (APL) and anticipated the current age of targeted cancer therapy. The past 25 years have seen an international effort to design multicenter clinical trials that identify the optimal use of ATRA in patients with APL. Indeed, since ATRA is so effective, contemporary clinical trials aim to de-escalate conventional cytotoxic chemotherapy, as has been the case with other highly curable malignancies such as childhood acute lymphoblastic leukemia and Hodgkin’s lymphoma. In this chapter, we review and reflect upon the seminal clinical trials that have led to the current adoption of ATRA as the standard of care for treating APL.

AB - All-trans retinoic acid (ATRA), an oral retinoic acid derivative, revolutionized the treatment and prognosis of acute promyelocytic leukemia (APL) and anticipated the current age of targeted cancer therapy. The past 25 years have seen an international effort to design multicenter clinical trials that identify the optimal use of ATRA in patients with APL. Indeed, since ATRA is so effective, contemporary clinical trials aim to de-escalate conventional cytotoxic chemotherapy, as has been the case with other highly curable malignancies such as childhood acute lymphoblastic leukemia and Hodgkin’s lymphoma. In this chapter, we review and reflect upon the seminal clinical trials that have led to the current adoption of ATRA as the standard of care for treating APL.

KW - Acute promyelocytic leukemia

KW - All-trans retinoic acid

KW - Consolidation

KW - Induction

KW - Maintenance

UR - http://www.scopus.com/inward/record.url?scp=84944575975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944575975&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1393-0_25

DO - 10.1007/978-1-4939-1393-0_25

M3 - Chapter

AN - SCOPUS:84944575975

SN - 9781493913923

SP - 489

EP - 507

BT - Targeted Therapy of Acute Myeloid Leukemi

PB - Springer New York

ER -

Targeting pml-rarα with retinoids

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this